Avenue Therapeutics, Inc.
NasdaqCM ATXI
Avenue Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -11.81 M
Avenue Therapeutics, Inc. Operating Income is USD -11.81 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 27.71% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
-
Avenue Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -16.33 M, a -223.98% change year over year.
-
Avenue Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -5.04 M, a -31.86% change year over year.
-
Avenue Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -3.82 M, a 60.54% change year over year.
-
Avenue Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -9.69 M, a 61.08% change year over year.
Key data
| Date | Operating Income | EBIT | EBITDA | Net Income |
|---|
Market news
Loading...
NasdaqCM: ATXI
| CEO | Dr. Alexandra MacLean M.D. |
| IPO Date | June 27, 2017 |
| Location | United States |
| Headquarters | 1140 Avenue of the America |
| Employees | 3 |
| Sector | Health Care |
| Industries | |
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Key trends
Past 5 years
Similar companies
Palisade Bio, Inc.
USD 1.75
-4.37%
Virax Biolabs Group Limited
USD 2.29
-3.78%
Allarity Therapeutics, Inc.
USD 1.01
-5.61%
Biodexa Pharmaceuticals Plc
USD 4.18
-2.79%
StockViz Staff
January 15, 2025
Any question? Send us an email